Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AVXL 
Anavex Life Sciences Corp (AVXL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: AVXL (3-star) is a STRONG-BUY. BUY since 5 days. Profits (1.94%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $34.33
Year Target Price $34.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 42.49% | Avg. Invested days 21 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 809.33M USD | Price to earnings Ratio - | 1Y Target Price 34.33 |
Price to earnings Ratio - | 1Y Target Price 34.33 | ||
Volume (30-day avg) - | Beta 0.67 | 52 Weeks Range 4.00 - 14.44 | Updated Date 06/29/2025 |
52 Weeks Range 4.00 - 14.44 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.44% | Return on Equity (TTM) -40.17% |
Valuation
Trailing PE - | Forward PE 4.03 | Enterprise Value 693554156 | Price to Sales(TTM) - |
Enterprise Value 693554156 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.54 | Shares Outstanding 85371904 | Shares Floating 82526408 |
Shares Outstanding 85371904 | Shares Floating 82526408 | ||
Percent Insiders 3.33 | Percent Institutions 37.67 |
Analyst Ratings
Rating 4.67 | Target Price 34.33 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Anavex Life Sciences Corp
Company Overview
History and Background
Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Founded in 2004, Anavex has focused on developing therapeutics using its SIGMAR1 receptor platform.
Core Business Areas
- Neurodegenerative Diseases: Developing therapeutics for diseases such as Alzheimer's disease, Parkinson's disease, and Rett syndrome, targeting the SIGMAR1 receptor to restore cellular homeostasis.
Leadership and Structure
Christopher U. Missling, PhD, is the President and Chief Executive Officer. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- ANAVEXu00ae2-73 (blarcamesine): An oral small molecule drug candidate currently in clinical trials for the treatment of Alzheimer's disease, Rett syndrome, and Parkinson's disease. Market share is currently 0 as the product is in clinical development. Competitors include Biogen (with Aduhelm and Leqembi), Eli Lilly (Donanemab), and Roche.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development. The market for neurodegenerative disease treatments is large and growing, driven by an aging population.
Positioning
Anavex is positioned as a company focused on innovative treatments for neurodegenerative diseases. Their competitive advantage lies in their SIGMAR1 receptor platform and potential for disease-modifying therapies.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of dollars. Anavex is positioned to capture a portion of this market if ANAVEXu00ae2-73 is approved.
Upturn SWOT Analysis
Strengths
- Novel SIGMAR1 receptor platform
- Promising clinical trial data for ANAVEXu00ae2-73
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Dependence on the success of ANAVEXu00ae2-73
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of SIGMAR1 platform to other diseases
Threats
- Clinical trial failures
- Competition from other companies developing similar therapies
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- RO
Competitive Landscape
Anavex faces significant competition from established pharmaceutical companies with greater resources and experience. Anavex's advantage is their unique approach to targeting the SIGMAR1 receptor.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on the advancement of ANAVEXu00ae2-73 through clinical trials.
Future Projections: Future growth is contingent on regulatory approval and successful commercialization of ANAVEXu00ae2-73.
Recent Initiatives: Focus on advancing ANAVEXu00ae2-73 through clinical trials for Alzheimer's disease, Rett syndrome, and Parkinson's disease. Exploring potential partnerships to support development and commercialization.
Summary
Anavex Life Sciences is a high-risk, high-reward biopharmaceutical company. The company's future hinges on the success of its lead drug candidate, ANAVEXu00ae2-73. Positive clinical trial results and regulatory approval could lead to substantial growth, while failures could significantly impact the company's value. Securing strategic partnerships would significantly derisk the drug development program
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anavex Life Sciences Corp
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-08-02 | President, CEO, Secretary & Director Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 42 | Website https://www.anavex.com |
Full time employees 42 | Website https://www.anavex.com | ||
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.